The aim of the study is to determine if single fraction dose escalated palliative radiotherapy results in a prolonged duration of benefit for patients otherwise suitable for Multifraction (5-10#) palliative radiation. The primary endpointis to determine the percentage of patients who have achieved a substantial benefit from palliative radiotherapy and have not redeveloped symptoms by 12 months post treatment
Metastatic cancer
Recommended for 5-10 fractions palliative radiation
Patients with spinal cord compression are eligible for enrolment
Unwilling or unable to give informed consent
Patients who are recommended for single fraction palliative radiation
Parallel
dose escalation
Radiationsingle fraction dose escalation to the tumour
benefit from palliative radiotherapy
to determine the percentage of patients who have achieved a substantial benefit from palliative radiotherapy and have not redeveloped symptoms by 9 months post treatment
Feasibility of the trial
This will be assessed by the treatment wait time, the amount of time spent in the Radiation Department, the completion rates of electronic Patient Reported Outcome (ePRO)'s and comparing patient and carer assessments
Trial Safety
this will be determined by the radiation dose delivered to organs at risk and patient and carer reported toxicity from treatment
Efficacy of treatment
Efficacy will be determined by reported treatment benefit, pain response, symptom control,re-treatment rates, overall survival and patient and carer regret
Map coordinates are unavailable for these locations. Locations are shown below instead.
AustraliaClick on the lead sponsor to view all of their trials.
Royal North Shore Hospital
Lead sponsor
Northern Sydney and Central Coast Area Health Service
Collaborator
